MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology ...
BioNTech (BNTX) on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 ...
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...
BioNTech reported Q1 revenue of $192.23 million, surpassing the consensus of $177.40 million. Cash and investments totaled 15.85 billion euros as of March 31, 2025. Geopolitical tensions, Fed ...
BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results